Employee stock plan registration
Open the filing on sec.gov
Nasus Pharma Ltd. (NSRX)
NYSE: NSRX · Pharmaceutical Preparations · Tel Aviv - Yafo, IL · filing with the SEC since 2024
The companyfiscal 2025, as filed
Revenue$1.24B
Net income-$5.9M-282.2%
Earnings per share$-0.72-227.3%
Operating cash flow-$4.9M-639.5%
Cash$1.2M+335.6%
Debtn/a
Shareholders’ equity$2.8M+186.2%
Shares, diluted8,010,126+14.0%
Return on equity-211.6%
The recordfrom its filings
Filings in 202650
Newest filingOct 19 · S-8
Annual reportMar 25, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$100,000
Patents granted3
Filer categoryNon-accelerated filer<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Interim report, foreign filer
Open the filing on sec.gov
Insider holding, initial
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Registration effective
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Shelf registration, foreign filer
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.